Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 322, Issue 11, 2019, Pages 1077-1084

  Desai, Akshay S ^a   Solomon, Scott D ^a   Shah, Amil M ^a   Claggett, Brian L ^a   Fang, James C ^b   Izzo, Joseph ^c   McCague, Kevin ^d   Abbas, Cheryl A ^d   Rocha, Ricardo ^d   Mitchell, Gary F ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e CARDIOVASCULAR ENGINEERING INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENALAPRIL; SACUBITRIL PLUS VALSARTAN;

ADVERSE OUTCOME; AGED; ARTERIAL STIFFNESS; CARDIOVASCULAR PARAMETERS; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GLOBAL LONGITUDINAL STRAIN; HEART EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE REMODELING; HUMAN; HYPERKALEMIA; HYPOTENSION; LEFT ATRIAL VOLUME INDEX; MAJOR CLINICAL STUDY; MALE; MITRAL ANNULAR RELAXATION VELOCITY; MITRAL E RATIO; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR VASCULAR COUPLING RATIO;

EID: 85071683129     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2019.12843     Document Type: Conference Paper

References (19)

1. McMurray JJ, Packer M, Desai AS,; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371 (11): 993-1004. doi: 10.1056/NEJMoa1409077 25176015
2. Böhm M, Young R, Jhund PS, Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF. Eur Heart J. 2017; 38 (15): 1132-1143. doi: 10.1093/eurheartj/ehw570 28158398
3. Yancy CW, Jessup M, Bozkurt B, 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017; 136 (6): E137-e161. doi: 10.1161/CIR.0000000000000509 28455343
4. Mitchell GF, Izzo JL Jr, Lacourcière Y, Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: Results of the Conduit Hemodynamics of Omapatrilat International Research Study. Circulation. 2002; 105 (25): 2955-2961. doi: 10.1161/01.CIR.0000020500.77568.3C 12081987
5. Williams B, Cockcroft JR, Kario K, Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER study. Hypertension. 2017; 69 (3): 411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556 28093466
6. Zile MR, O'Meara E, Claggett B, Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019; 73 (7): 795-806. doi: 10.1016/j.jacc.2018.11.042 30784673
7. Mitchell GF, Wang N, Palmisano JN, Hemodynamic correlates of blood pressure across the adult age spectrum: Noninvasive evaluation in the Framingham Heart Study. Circulation. 2010; 122 (14): 1379-1386. doi: 10.1161/CIRCULATIONAHA.109.914507 20855656
8. Chirinos JA, Segers P, Gillebert TC,; Asklepios Investigators. Arterial properties as determinants of time-varying myocardial stress in humans. Hypertension. 2012; 60 (1): 64-70. doi: 10.1161/HYPERTENSIONAHA.112.190710 22665121
9. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol. 2000; 35 (5): 1245-1255. doi: 10.1016/S0735-1097(00)00531-3 10758967
10. Spertus J, Peterson E, Conard MW,; Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: A comparison of methods. Am Heart J. 2005; 150 (4): 707-715. doi: 10.1016/j.ahj.2004.12.010 16209970
11. Lang RM, Badano LP, Mor-Avi V, Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28 (1): 1-39. doi: 10.1016/j.echo.2014.10.003 25559473
12. Nagueh SF, Smiseth OA, Appleton CP, Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29 (4): 277-314. doi: 10.1016/j.echo.2016.01.011 27037982
13. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Cardiol Clin. 2011; 29 (3): 447-459. doi: 10.1016/j.ccl.2011.06.004 21803232
14. Mitchell GF, Tardif JC, Arnold JM, Pulsatile hemodynamics in congestive heart failure. Hypertension. 2001; 38 (6): 1433-1439. doi: 10.1161/hy1201.098298 11751731
15. Mitchell GF, Arnold JM, Dunlap ME, Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: The CHARM program. Eur J Heart Fail. 2006; 8 (2): 191-197. doi: 10.1016/j.ejheart.2005.07.006 16188495
16. Packer M, McMurray JJ, Desai AS,; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015; 131 (1): 54-61. doi: 10.1161/CIRCULATIONAHA.114.013748 25403646
17. Velazquez EJ, Morrow DA, DeVore AD,; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380 (6): 539-548. doi: 10.1056/NEJMoa1812851 30415601
18. Lewis EF, Claggett BL, McMurray JJV, Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017; 10 (8): E003430. doi: 10.1161/CIRCHEARTFAILURE.116.003430 28784687
19. Kang DH, Park SJ, Shin SH, Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019; 139 (11): 1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077 30586756